TAT3 contributes to cisplatin resistance, modulating EMT markers, and the mTOR signaling in lung adenocarcinom

Autor(es):Mostrar menos -

Morelli, Ana Paula ^[1] ; Tortelli Jr, Tharcisio Citrangulo ; Silva Mancini, Mariana Camargo ^[1] ; Betim Pavan, Isadora Carolina ^{[1, 2]} ; Salvino Silva, Luiz Guilherme ^[1] ; Severino, Matheus Brandemarte ^[1] ; Granato, Daniela Campos ^[3] ; Pestana, Nathalie Fortes ^[1] ; Saboia Ponte, Luis Gustavo ^[1] ; Peruca, Guilherme Francisco ^[4] ; Pauletti, Bianca Alves ^[3] ; Guimaraes dos Santos Jr, Daniel Francisco ; de Moura, Leandro Pereira ^[4] ; Neves Bezerra, Rosangela Maria ^[5] ; Paes Leme, Adriana Franco ^[3] ; Chammas, Roger ^{[6, 7]} ; Simabuco, Fernando Moreira ^{[5, 4]}

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas, Sch Appl Sci, Multidisciplinary Lab Food & Hlth, Limeira, SP - Brazil

^[2] Univ Estadual Campinas, Lab Signaling Mech, Sch Pharmaceut Sci, Campinas, SP - Brazil

^[3] Ctr Nacl Pesquisa Energia & Mat CNPEM, Lab Nacl Biociencias LNBio, Campinas, SP - Brazil

^[4] Univ Estadual Campinas, Sch Appl Sci, Exercise Cell Biol Lab, Limeira, SP - Brazil

^[5] Guimaraes dos Santos Jr, Jr., Daniel Francisco, Univ Estadual Campinas, Sch Appl Sci, Multidisciplinary Lab Food & Hlth, Limeira, SP - Brazil

^[6] Tortelli Jr, Jr., Tharcisio Citrangulo, Univ Sao Paulo, Ctr Invest Translac Oncol, Dept Radiol & Oncol, Fac Med, Sao Paulo, SP - Brazil

^[7] Tortelli Jr, Jr., Tharcisio Citrangulo, Inst Canc Estado de Sao Paulo, Sao Paulo, SP - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Neoplasia; v. 23, n. 10, p. 1048-1058, OCT 2021.
• Citações Web of Science: 0

Resumo

Lung cancer is the second leading cause of cancer death worldwide and is strongly associated with cisplatin resistance. The transcription factor signal transducer and activator of transcription 3 (STAT3) is constitutively activated in cancer cells and coordinates critical cellular processes as survival, self-renewal, and inflammation. In several types of cancer, STAT3 controls the development, immunogenicity, and malignant behavior of tumor cells while it dictates the responsiveness to radio- and chemotherapy. It is known that STAT3 phosphorylation at Ser727 by mechanistic target of rapamycin (mTOR) is necessary for its maximal activation, but the crosstalk between STAT3 and mTOR signaling in cisplatin resistance remains elusive. In this study, using a proteomic approach, we revealed important targets and signaling pathways altered in cisplatin-resistant A549 lung adenocarcinoma cells. STAT3 had increased expression in a resistance context, which can be associated with a poor prognosis. STAT3 knockout (SKO) resulted in a decreased mesenchymal phenotype in A549 cells, observed by clonogenic potential and by the expression of epithelial-mesenchymal transition markers. Importantly, SKO cells did not acquire the mTOR pathway overactivation induced by cisplatin resistance. Consistently, SKO cells were more responsive to mTOR inhibition by rapamycin and presented impairment of the feedback activation loop in Akt. Therefore, rapamycin was even more potent in inhibiting the clonogenic potential in SKO cells and sensitized to cisplatin treatment. Mechanistically, STAT3 partially coordinated the cisplatin resistance phenotype via the mTOR pathway in non-small cell lung cancer. Thus, our findings reveal important targets and highlight the significance of the crosstalk between STAT3 and mTOR signaling in cisplatin resistance. The synergic inhibition of STAT3 and mTOR potentially unveil a potential mechanism of synthetic lethality to be explored for human lung cancer treatment. (AU)

• Processo FAPESP: 19/25582-9 - Estudo do papel da proteína Nrf2 na regulação do metabolismo e controle redox em resposta a compostos naturais derivados de alimentos em células de Câncer de Próstata
• Beneficiário: Mariana Camargo Silva Mancini
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 15/22814-5 - Câncer e coração: novos paradigmas de diagnóstico e tratamento
• Beneficiário: Carlos Eduardo Negrão
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 15/00311-1 - Caracterização funcional de proteínas de interação das diferentes isoformas de S6Ks
• Beneficiário: Isadora Carolina Betim Pavan
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 18/14818-9 - Estudo de alvos moleculares importantes para o controle do metabolismo em câncer: a via da mTOR/S6K com papel central
• Beneficiário: Fernando Moreira Simabuco
• Modalidade de apoio: Auxílio à Pesquisa - Jovens Pesquisadores - Fase 2
• Processo FAPESP: 19/00607-9 - Caracterização de alvos moleculares envolvidos na resistência quimioterápica e no metabolismo tumoral de células de câncer de pulmão
• Beneficiário: Ana Paula Morelli
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 20/09527-5 - Estudo do papel da proteína Nsp9 do SARS-CoV-2 no estresse oxidativo: nutracêuticos como uma abordagem terapêutica
• Beneficiário: Luiz Guilherme Salvino da Silva
• Modalidade de apoio: Bolsas no Brasil - Doutorado